Clinical importance of the presence of giant cells in temporal arteritis
- PMID: 18326013
- DOI: 10.1136/jcp.2007.049049
Clinical importance of the presence of giant cells in temporal arteritis
Abstract
Background: The clinical significance of giant cells seen on temporal artery biopsy in temporal arteritis is unknown.
Aim: To help define the prognostic value of the presence of giant cells in temporal arteritis.
Methods: The clinical course of all patients with biopsy proven temporal arteritis from 1994 to 2004 was reviewed. The 92 patients were divided into those with giant cells (GC) (n = 76) seen on biopsy and those with no giant cells (NGC) (n = 16). Clinical findings were compared between groups. An additional analysis combined results with a previous study at the same institution to compare occurrence of blindness.
Results: The GC group had a higher proportion of polymyalgia rheumatica (PMR) (36.8%) compared to the NGC group (12.5%) (p = 0.059). There was no significant difference in patient age, sex, sedimentation rate, or presenting symptoms. The length of time treated with corticosteroids and relapse rate was nearly identical for both groups. When combining data with the previous study, in the GC group 21/109 (19%) developed blindness, while only 2/34 (6%) became blind in the NGC group (p = 0.11).
Conclusion: The presence of giant cells is not a significant factor in determining treatment or clinical progression of temporal arteritis. However, results showed the GC group to have three times the occurrence of blindness and PMR compared to the NGC group. Although the differences were not significant, this analysis suggests an association with giant cells and more aggressive disease.
Similar articles
-
Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica.J Rheumatol. 1998 Sep;25(9):1750-5. J Rheumatol. 1998. PMID: 9733456
-
Small-vessel vasculitis surrounding an uninflamed temporal artery: a new diagnostic criterion for polymyalgia rheumatica?Arthritis Rheum. 2008 Aug;58(8):2565-73. doi: 10.1002/art.23700. Arthritis Rheum. 2008. PMID: 18668584
-
[Diagnostic value of clinical signs in giant cell arteritis: analysis of 415 temporal artery biopsy findings].Ann Med Interne (Paris). 2002 Feb;153(1):3-12. Ann Med Interne (Paris). 2002. PMID: 11994684 French.
-
[Giant cell arteritis. A study of 191 patients].Med Clin (Barc). 1995 Dec 2;105(19):734-7. Med Clin (Barc). 1995. PMID: 8523954 Review. Spanish.
-
Giant cell arteritis.Curr Opin Rheumatol. 1992 Feb;4(1):23-30. Curr Opin Rheumatol. 1992. PMID: 1543659 Review.
Cited by
-
Giant Cell Arteritis: Advances in Understanding Pathogenesis and Implications for Clinical Practice.Cells. 2024 Jan 31;13(3):267. doi: 10.3390/cells13030267. Cells. 2024. PMID: 38334659 Free PMC article. Review.
-
Description and Validation of Histological Patterns and Proposal of a Dynamic Model of Inflammatory Infiltration in Giant-cell Arteritis.Medicine (Baltimore). 2016 Feb;95(8):e2368. doi: 10.1097/MD.0000000000002368. Medicine (Baltimore). 2016. PMID: 26937893 Free PMC article.
-
Pathogenesis of giant cell arteritis with focus on cellular populations.Front Med (Lausanne). 2022 Nov 17;9:1058600. doi: 10.3389/fmed.2022.1058600. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36465919 Free PMC article. Review.
-
Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?Arthritis Rheumatol. 2018 Sep;70(9):1366-1376. doi: 10.1002/art.40520. Epub 2018 Jul 30. Arthritis Rheumatol. 2018. PMID: 29648680 Free PMC article. Review.
-
The Immunopathology of Giant Cell Arteritis Across Disease Spectra.Front Immunol. 2021 Feb 25;12:623716. doi: 10.3389/fimmu.2021.623716. eCollection 2021. Front Immunol. 2021. PMID: 33717128 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous